There are a number of contenders hoping to get into the hidradenitis suppurativa (HS) market soon but they will have to play catch with Novartis AG's Cosentyx which has just received a green light in the EU for the chronic inflammatory skin disease.
The European Commission has approved Cosentyx (secukinumab) for use in adults with active moderate to severe HS who have had an inadequate response to conventional systemic therapy